as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 29 Sep 2026
₹161.39
Change
-2.88 (-1.75%)
Open
₹164.3
Prev. Close
₹164.27
Day High
₹166.49
Day Low
₹160.99
Volume Analysis
Traded
260,096
Delivered
159,426
Delivery %
61.3%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (2)
- •Low return on equity (1.58%)
- •Below-average fundamentals quality score (44/100)
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹170.43 | ₹168.46 | ₹164.93 | ₹162.96 | ₹159.43 | ₹157.46 | ₹153.93 |
| Fibonacci | ₹168.46 | ₹166.36 | ₹165.06 | ₹162.96 | ₹160.86 | ₹159.56 | ₹157.46 |
| Camarilla | ₹162.9 | ₹162.4 | ₹161.89 | ₹162.96 | ₹160.89 | ₹160.38 | ₹159.88 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-37.08%
1 Week
-6.89%
1 Month
-9.5%
3 Months
-14.04%
6 Months
+9.42%
1 Year
-41.44%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹244.17
Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
0.24%
Net margin 0.55% × asset turnover 0.25x × equity multiplier 1.78x
Company Overview
Sector
Healthcare
Market Cap
₹2,546 Cr
P/E (TTM)
140.0
ROE
1.58%
Book Value
₹426.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 29 Sep 2026. Not investment advice.
TopFund Analysis
Dishman Carbo Amcis Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 44/100. The strongest factor is Financial Strength (91/100), while Risk & Volatility (15/100) is the weakest area to weigh before deciding. Notably: Low return on equity (1.58%); below-average fundamentals quality score (44/100). FII holding has been falling.
TopFund Score — Fundamentals Quality
44/100 — WeakData confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 29 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Stock is trading at 0.40 times its book value
- +Company has delivered good profit growth of 20.9% CAGR over last 5 years
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of 8.93% over past five years.
- −Company has a low return on equity of -0.40% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Allotted 1,500 NCDs of ₹1 lakh each, raising ₹15 crore; maturity March 28, 2028.
CARBOGEN AMCIS AG’s Vionnaz, Switzerland site cleared first US FDA inspection on 11 September 2026 without Form 483.
Newspaper advertisement for 19th AGM and e-voting notice; AGM scheduled on 30 September 2026.
19th AGM on 30 September 2026 via VC/OAVM; annual report for FY2025-26 submitted.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 723 | 587 | 651 | 655 | 524 | 789 | 682 | 716 | 708 | 653 | 720 | 851 | 678 |
| Expenses + | 602 | 526 | 610 | 592 | 495 | 642 | 542 | 564 | 567 | 504 | 607 | 688 | 618 |
| Operating Profit | 122 | 61 | 41 | 63 | 29 | 147 | 140 | 153 | 141 | 149 | 113 | 163 | 60 |
| OPM % | 17.0% | 10.0% | 6.0% | 10.0% | 6.0% | 19.0% | 21.0% | 21.0% | 20.0% | 23.0% | 16.0% | 19.0% | 9.0% |
| Other Income + | 7 | 5 | 6 | 4 | -4 | 4 | 8 | -4 | 22 | 8 | 7 | 15 | 16 |
| Interest | 28 | 27 | 33 | 31 | 32 | 37 | 49 | 42 | 43 | 42 | 46 | 43 | 37 |
| Depreciation | 70 | 75 | 80 | 85 | 71 | 72 | 72 | 79 | 81 | 84 | 84 | 89 | 91 |
| Profit before tax | 29 | -36 | -66 | -49 | -78 | 42 | 27 | 28 | 39 | 31 | -10 | 46 | -51 |
| Tax % | 42.0% | 13.0% | -10.0% | 42.0% | 0.0% | 21.0% | 83.0% | -56.0% | 39.0% | -114.0% | 24.0% | 53.0% | 13.0% |
| Net Profit + | 17 | -41 | -60 | -70 | -78 | 33 | 5 | 43 | 23 | 65 | -13 | 22 | -58 |
| EPS in Rs | 1 | -3 | -4 | -4 | -5 | 2 | 0 | 3 | 1 | 4 | -1 | 1 | -4 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,031 | 1,714 | 1,695 | 2,059 | 2,044 | 1,912 | 2,141 | 2,413 | 2,616 | 2,712 | 2,932 | 2,901 |
| Expenses + | 830 | 1,261 | 1,249 | 1,507 | 1,540 | 1,638 | 1,809 | 2,081 | 2,329 | 2,243 | 2,366 | 2,416 |
| Operating Profit | 201 | 452 | 445 | 552 | 503 | 274 | 331 | 332 | 286 | 469 | 566 | 485 |
| OPM % | 20.0% | 26.0% | 26.0% | 27.0% | 25.0% | 14.0% | 15.0% | 14.0% | 11.0% | 17.0% | 19.0% | 17.0% |
| Other Income + | 14 | 26 | 46 | 54 | 39 | 16 | 29 | -20 | 22 | 4 | 52 | 47 |
| Interest | 56 | 49 | 49 | 57 | 62 | 48 | 57 | 86 | 120 | 159 | 174 | 169 |
| Depreciation | 69 | 214 | 211 | 240 | 283 | 308 | 308 | 281 | 311 | 294 | 339 | 348 |
| Profit before tax | 91 | 216 | 231 | 309 | 197 | -65 | -4 | -55 | -122 | 19 | 105 | 15 |
| Tax % | 12.0% | 33.0% | 33.0% | 32.0% | 20.0% | 154.0% | -524.0% | -45.0% | 26.0% | 83.0% | 7.0% | — |
| Net Profit + | 80 | 145 | 155 | 210 | 159 | -165 | 18 | -30 | -153 | 3 | 97 | 16 |
| EPS in Rs | — | — | 10 | 13 | 10 | -11 | 1 | -2 | -10 | 0 | 6 | 1 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 2.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 863 | 4,814 | 5,075 | 5,347 | 5,684 | 5,667 | 5,518 | 5,778 | 5,596 | 5,800 | 6,646 |
| Borrowings + | 868 | 950 | 1,095 | 1,042 | 1,357 | 1,589 | 1,830 | 2,209 | 2,313 | 2,389 | 3,076 |
| Other Liabilities + | 334 | 811 | 967 | 899 | 1,121 | 1,068 | 1,255 | 1,421 | 1,631 | 1,766 | 2,158 |
| Total Liabilities | 2,081 | 6,574 | 7,169 | 7,321 | 8,193 | 8,356 | 8,634 | 9,439 | 9,571 | 9,987 | 11,911 |
| Fixed Assets + | 1,012 | 4,852 | 5,066 | 5,098 | 5,678 | 5,698 | 5,773 | 6,188 | 6,724 | 7,055 | 8,076 |
| CWIP | 307 | 133 | 151 | 175 | 234 | 486 | 780 | 1,043 | 646 | 467 | 570 |
| Investments | 1 | 40 | 196 | 167 | 191 | 172 | 324 | 249 | 102 | 97 | 91 |
| Other Assets + | 761 | 1,550 | 1,757 | 1,881 | 2,091 | 2,000 | 1,758 | 1,959 | 2,098 | 2,368 | 3,174 |
| Total Assets | 2,081 | 6,574 | 7,169 | 7,321 | 8,193 | 8,356 | 8,634 | 9,439 | 9,571 | 9,987 | 11,911 |
| Equity Capital | 16 | 0 | 32 | 32 | 31 | 31 | 31 | 31 | 31 | 31 | 31 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 203 | 303 | 226 | 282 | 585 | 513 | 355 | 266 | 379 | 371 | 491 |
| Cash from Investing Activity + | -231 | -107 | -297 | -169 | -442 | -380 | -619 | -494 | -225 | -192 | -245 |
| Cash from Financing Activity + | 25 | -137 | 78 | -102 | -98 | -11 | 130 | 250 | -22 | -102 | 201 |
| Net Cash Flow | -3 | 59 | 7 | 11 | 46 | 122 | -133 | 22 | 132 | 77 | 447 |
| CFO/OP | 107 | 92 | 58 | 75 | 131 | 206 | 124 | 90 | 139 | 86 | 88 |
| Free Cash Flow | -37 | 164 | 22 | -26 | 177 | 147 | -101 | -352 | 76 | 156 | 225 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 28.37% | 28.39% | 29.63% | 31.17% | 31.29% | 30.51% | 29.94% | 29.48% | 31.23% | 31.75% | 31.6% | 31.76% |
| Promoters | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% |
| FII | 8.8% | 8.6% | 8.7% | 8.05% | 8.18% | 8.75% | 9.49% | 9.94% | 8.07% | 7.66% | 7.45% | 6.86% |
| DII | 3.51% | 3.68% | 2.36% | 1.47% | 1.22% | 1.42% | 1.26% | 1.27% | 1.37% | 1.27% | 1.63% | 2.06% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Dishman Carbo Amcis Ltd (this stock) | 2,546 | 140.0 | 0.38 | 1.58% |
| Sakar Healthcare Limited | 2,527 | 70.0 | 7.78 | 9.99% |
| Shukra Pharmaceuticals L | 2,465 | 72.6 | 27.27 | 28.9% |
| Vimta Labs Limited | 2,679 | 44.1 | 7.76 | 13.5% |
| Hikal Limited | 2,687 | 63.4 | 2.24 | 2.21% |
| Fischer Medical Venture L | 2,355 | 96.2 | 5.73 | 8.91% |
| Indoco Remedies Ltd. | 2,306 | — | 2.45 | -9.36% |
Which Mutual Funds Hold Dishman Carbo Amcis Ltd?
Frequently Asked Questions about Dishman Carbo Amcis Ltd
Dishman Carbo Amcis Ltd (DCAL) closed at ₹161.39 on NSE on 29 September 2026, down 2.88 (1.75%) from the previous close.
Dishman Carbo Amcis Ltd trades on the NSE (National Stock Exchange of India) under the symbol DCAL.
Dishman Carbo Amcis Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 140.0.
Dishman Carbo Amcis Ltd has a dividend yield of 0.0%.
Dishman Carbo Amcis Ltd's 52-week high is ₹307.0 and its 52-week low is ₹128.0.
Dishman Carbo Amcis Ltd has a market capitalisation of ₹2,546 crore.
Dishman Carbo Amcis Ltd has a TopFund Quality Score of 44/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Dishman Carbo Amcis Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.